Hyoungmin Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyoungmin Cho has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hanbyeol Park
Institute for New Drug Development, Division of Life Sciences, Incheon National University, Incheon 22012, Republic of Korea
1 shared publication - Myeongjin Jeon
Research Center, Samjin Pharm. Co., Ltd., Seoul 07794, Republic of Korea
1 shared publication - Soo-Min Lee
Samjin Pharmaceutical Co., Ltd., Seoul 04054, Republic of Korea
1 shared publication - Soon Kil Ahn
Institute for New Drug Development, Division of Life Sciences Incheon National University Incheon Republic of Korea
1 shared publication - Sungpyo Hong
Institute for New Drug Development, Division of Life Sciences, Incheon National University, Incheon 22012, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 24 August 2023
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 45 (9) , 7058-7074
Targeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) presents significant challenges due to its aggressive nature and limited treatment options. Focal adhesion kinase (FAK) has emerged as a critical factor promoting tumor growth and metastasis in TNBC. Despite encouraging results from preclinical and early clinical trials with various FAK inhibitors, none have yet achieved clinical success in TNBC treatment. This study investigates the therapeutic potential of a novel dual inhibitor of FAK and PYK2, named SJP1602, for TNBC. In vitro experiments demonstrate that SJP1602 effectively inhibits FAK and PYK2 activities, showing potent effects on both kinases. SJP1602 shows concentration-dependent inhibition of cell growth, migration, invasion, and 3D spheroid formation in TNBC cell lines, surpassing the efficacy of other FAK inhibitors. Pharmacokinetic studies in rats indicate favorable bioavailability and sustained plasma concentrations of SJP1602, supporting its potential as a therapeutic agent. Furthermore, in TNBC xenograft models, SJP1602 exhibits significant dose-dependent inhibition of tumor growth. These promising results emphasize the potential of SJP1602 as a potent dual inhibitor of FAK and PYK2, deserving further investigation in clinical trials for TNBC treatment.
- 24 August 2023
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 45 (9) , 7058-7074
Open AccessTargeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) presents significant challenges due to its aggressive nature and limited treatment options. Focal adhesion kinase (FAK) has emerged as a critical factor promoting tumor growth and metastasis in TNBC. Despite encouraging results from preclinical and early clinical trials with various FAK inhibitors, none have yet achieved clinical success in TNBC treatment. This study investigates the therapeutic potential of a novel dual inhibitor of FAK and PYK2, named SJP1602, for TNBC. In vitro experiments demonstrate that SJP1602 effectively inhibits FAK and PYK2 activities, showing potent effects on both kinases. SJP1602 shows concentration-dependent inhibition of cell growth, migration, invasion, and 3D spheroid formation in TNBC cell lines, surpassing the efficacy of other FAK inhibitors. Pharmacokinetic studies in rats indicate favorable bioavailability and sustained plasma concentrations of SJP1602, supporting its potential as a therapeutic agent. Furthermore, in TNBC xenograft models, SJP1602 exhibits significant dose-dependent inhibition of tumor growth. These promising results emphasize the potential of SJP1602 as a potent dual inhibitor of FAK and PYK2, deserving further investigation in clinical trials for TNBC treatment.